HUP0401300A3 - Bifunctional fusion proteins with glucocerebrosidase activity - Google Patents
Bifunctional fusion proteins with glucocerebrosidase activityInfo
- Publication number
- HUP0401300A3 HUP0401300A3 HU0401300A HUP0401300A HUP0401300A3 HU P0401300 A3 HUP0401300 A3 HU P0401300A3 HU 0401300 A HU0401300 A HU 0401300A HU P0401300 A HUP0401300 A HU P0401300A HU P0401300 A3 HUP0401300 A3 HU P0401300A3
- Authority
- HU
- Hungary
- Prior art keywords
- fusion proteins
- bifunctional fusion
- glucocerebrosidase activity
- glucocerebrosidase
- activity
- Prior art date
Links
- 102000004547 Glucosylceramidase Human genes 0.000 title 1
- 108010017544 Glucosylceramidase Proteins 0.000 title 1
- 230000001588 bifunctional effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01101056 | 2001-01-18 | ||
PCT/EP2001/015328 WO2002057435A2 (en) | 2001-01-18 | 2001-12-27 | Bifunctional fusion proteins with glucocerebrosidase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401300A2 HUP0401300A2 (hu) | 2004-09-28 |
HUP0401300A3 true HUP0401300A3 (en) | 2005-06-28 |
Family
ID=8176235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401300A HUP0401300A3 (en) | 2001-01-18 | 2001-12-27 | Bifunctional fusion proteins with glucocerebrosidase activity |
Country Status (13)
Country | Link |
---|---|
US (1) | US20040043457A1 (hu) |
EP (1) | EP1392826A2 (hu) |
JP (1) | JP2004525621A (hu) |
KR (1) | KR20030067755A (hu) |
CN (1) | CN1630720A (hu) |
BR (1) | BR0116803A (hu) |
CA (1) | CA2435037A1 (hu) |
HU (1) | HUP0401300A3 (hu) |
MX (1) | MXPA03006294A (hu) |
NO (1) | NO20033247L (hu) |
PL (1) | PL362394A1 (hu) |
WO (1) | WO2002057435A2 (hu) |
ZA (1) | ZA200306333B (hu) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1037927T3 (da) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
EP1071468B1 (en) * | 1998-04-15 | 2006-06-14 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
DE60122286T2 (de) * | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
BR0112111A (pt) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina |
CA2440221C (en) * | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
WO2003048334A2 (en) * | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
WO2005063820A2 (en) * | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
EP1699821B1 (en) * | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
KR20070085886A (ko) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | 감소된 면역원성의 il-7 변이체 |
CA2658673A1 (en) | 2005-07-27 | 2008-02-01 | Gerald J. Prud'homme | Composition and method for prevention and treatment of type i and type ii diabetes |
JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
JP5175214B2 (ja) * | 2005-12-30 | 2013-04-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 改良された安定性を有するインターロイキン−12p40変種 |
BRPI0620795A2 (pt) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschronkter Haftung | anticorpos anti-cd19 imunogenicidade reduzida |
EP1986612B1 (en) | 2006-02-07 | 2012-09-12 | Shire Human Genetic Therapies, Inc. | Stabilized composition of glucocerebrosidase |
WO2007104034A2 (en) | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
US8748567B2 (en) * | 2006-05-22 | 2014-06-10 | Children's Medical Center Corporation | Method for delivery across the blood brain barrier |
US8008332B2 (en) | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
EP2192924B1 (en) | 2007-08-20 | 2017-10-11 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
CN102405230A (zh) * | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | 具有修饰的FcRn结合位点的抗体融合蛋白 |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
EA201890254A3 (ru) * | 2009-11-27 | 2019-02-28 | Джензим Корпорэйшн | Ингибиторы глюкозилцерамидсинтазы |
EP2542572B1 (en) * | 2010-03-02 | 2015-05-06 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
EP2665814B1 (en) | 2011-01-20 | 2017-05-17 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
JOP20140087B1 (ar) * | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015237176A1 (en) * | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US20200157172A1 (en) * | 2017-07-07 | 2020-05-21 | HANMl PHARM. CO., LTD. | Novel therapeutic enzyme fusion protein and use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6475486B1 (en) * | 1990-10-18 | 2002-11-05 | Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
AU5065198A (en) * | 1996-11-15 | 1998-06-10 | Maria Grazia Masucci | Fusion proteins having increased half-lives |
JP4086908B2 (ja) * | 1997-04-17 | 2008-05-14 | アムジエン・インコーポレーテツド | 安定かつ活性なヒトOBタンパク質と抗体Fc鎖とのコンジュゲートを含む組成物および方法 |
CA2328614C (en) * | 1999-02-12 | 2012-06-26 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
JP2003522806A (ja) * | 2000-02-15 | 2003-07-29 | ジェンザイム、コーポレーション | 改良された薬物送達のための生体高分子の修飾 |
DE10102053A1 (de) * | 2001-01-17 | 2002-07-18 | Merck Patent Gmbh | Piperazinylcarbonylchinoline und -isochinoline |
-
2001
- 2001-12-27 US US10/466,593 patent/US20040043457A1/en not_active Abandoned
- 2001-12-27 PL PL01362394A patent/PL362394A1/xx unknown
- 2001-12-27 EP EP01989057A patent/EP1392826A2/en not_active Withdrawn
- 2001-12-27 WO PCT/EP2001/015328 patent/WO2002057435A2/en active Search and Examination
- 2001-12-27 BR BR0116803-7A patent/BR0116803A/pt not_active IP Right Cessation
- 2001-12-27 HU HU0401300A patent/HUP0401300A3/hu unknown
- 2001-12-27 CA CA002435037A patent/CA2435037A1/en not_active Abandoned
- 2001-12-27 MX MXPA03006294A patent/MXPA03006294A/es unknown
- 2001-12-27 KR KR10-2003-7009521A patent/KR20030067755A/ko not_active Application Discontinuation
- 2001-12-27 CN CNA018220797A patent/CN1630720A/zh active Pending
- 2001-12-27 JP JP2002558488A patent/JP2004525621A/ja not_active Withdrawn
-
2003
- 2003-07-17 NO NO20033247A patent/NO20033247L/no unknown
- 2003-08-14 ZA ZA200306333A patent/ZA200306333B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2435037A1 (en) | 2002-07-25 |
WO2002057435A2 (en) | 2002-07-25 |
ZA200306333B (en) | 2004-11-17 |
NO20033247D0 (no) | 2003-07-17 |
JP2004525621A (ja) | 2004-08-26 |
NO20033247L (no) | 2003-07-17 |
HUP0401300A2 (hu) | 2004-09-28 |
US20040043457A1 (en) | 2004-03-04 |
EP1392826A2 (en) | 2004-03-03 |
KR20030067755A (ko) | 2003-08-14 |
MXPA03006294A (es) | 2003-09-16 |
BR0116803A (pt) | 2004-02-17 |
PL362394A1 (en) | 2004-11-02 |
WO2002057435A3 (en) | 2003-12-24 |
CN1630720A (zh) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401300A3 (en) | Bifunctional fusion proteins with glucocerebrosidase activity | |
AU2002300734A1 (en) | Fusion protein having enhanced in vivo erythropoietin activity | |
IL166751A0 (en) | Modified transferin-antibody fusion proteins | |
PL362324A1 (en) | Artificial fusion proteins with reduced immunogenicity | |
AU6058500A (en) | Fusion protein and uses thereof | |
HUP0201801A2 (en) | Integral joining | |
EP1463751A4 (en) | HYBRID PROTEINS OF ALBUMIN | |
GB0009093D0 (en) | Goggles assembly | |
AU2001291049A1 (en) | Defensin-antigen fusion proteins | |
ZA200206172B (en) | Fusion protein having enhanced in vivo activity of erythropoietin. | |
AU2002300359A1 (en) | Fusion Protein Having Enhanced in vivo Activity of Erythropoietin | |
GB9913437D0 (en) | Fusion proteins | |
GB9921125D0 (en) | Proteins | |
GB9926084D0 (en) | Recombinant fusion molecules | |
IL148550A0 (en) | Transgenically produced fusion proteins | |
AU2002357891A8 (en) | Dtat fusion toxin | |
GB0200689D0 (en) | Fusion proteins | |
EP1392204A4 (en) | BIFUNCTIONAL ENERGY REVERSIBLE ACYL COMPOSITIONS | |
IL149202A0 (en) | Hedgehog fusion proteins and uses | |
GB9927681D0 (en) | Protein | |
IL148549A0 (en) | Subunit optimized fusion proteins | |
IL150134A0 (en) | Apoptin-associating protein | |
EP1209231A4 (en) | MEG-1 PROTEIN | |
GB9924060D0 (en) | VIP54 protein | |
EP1188828A4 (en) | REG-BINDING PROTEIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |